The ultimate goal of precision medicine is a unique drug for each patient. However, this N-of-1 model directly conflicts with the current economic and regulatory system, which incentivizes developing drugs for large populations to recoup massive R&D and approval costs.

Pharmaceutical companies structure deals around specific drug assets with clear milestones. They lack established business models for collaborating with AI companies offering platform technologies, creating a significant hurdle for tech bio startups seeking partnership.

The combination of AI reasoning and robotic labs could create a new model for biotech entrepreneurship. It enables individual scientists with strong ideas to test hypotheses and generate data without raising millions for a physical lab and staff, much like cloud computing lowered the barrier for software startups.

AI strategies often fail to get sustained funding because they lack detailed financial models beyond simple cost savings. A credible blueprint must quantify projected revenue uplift for each initiative, a step often skipped because strategists lack the deep pharma AI experience to make accurate forecasts.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

The future of AI in drug discovery is shifting from merely speeding up existing processes to inventing novel therapeutics from scratch. The paradigm will move toward AI-designed drugs validated with minimal wet lab reliance, changing the key question from "How fast can AI help?" to "What can AI create?"

As AI models become adept at identifying novel or experimental treatments for individuals, it will create mounting pressure on the medical regulatory system. Patients, armed with compelling, AI-generated arguments for a specific therapy, will increasingly challenge the gates kept by establishments, potentially forcing an evolution of the social contract around access to unproven medicines ('right to try').

For patients with ultra-rare diseases, traditional drug development is too slow. AI platforms like Therna's can design a custom RNA molecule in days and complete the lab-testing cycle in under three months, compressing a multi-year process and making previously impossible treatments viable.

Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.